Arch rivals are grouping to look for a lasting solution to what external subject experts call “deeply ingrained culture issue”.

Sources indicated that Indian drug makers will be keen to buy the generic portfolio on offer, which could be valued at a minimum of $500 mi...

Flipkart, enjoys a valuation that's more than that of brick-and-mortar giants like Indian Oil Corporation ($14.3 billion), Tata Motors ($13...

The State Bank of India had said earlier that it was also exploring ways to declare Vijay Mallya as a willful defaulter.

United Bank of India has taken action against four loan defaulters in an attempt to reduce its non-performing loans.

Competition Commission of India (CCI) has approved Japanese firm Mitsui's proposed takeover of 26.71 per cent stake in domestic biopharmace...

The falsification of accounts by Satyam for the past several years has put a question mark on the very survival of its auditor, Pricewaterh...

Ranbaxy has entered into a series of out-of-court settlements with AstraZeneca with estimates of a revenue upside of $1.25-1.5 billion. Go ...

Solrex will have to fork out an extra Rs 400-500 crore to buy a further 20% stake in case it comes with an open offer.

Healthcare groups, campaigning for access to medicines, are going all out in their fight against drug patents in India.

Pfizer has filed two separate patent infringement cases against Ranbaxy in a bid to extend the exclusivity of its $13-billion anti-choleste...

The industry feels that govt's support in the form of apparent attractive tax incentives would do very little to provide growth stimulus. H...

The Delhi HC rejected an injunction plea by Swiss drug major Roche to prevent Cipla from manufacturing generic versions of anti-cancer drug...

In what could be a setback for Ranbaxy and a few other companies, the government has endorsed the pharma price regulator’s decision to fix ...

Following finance minister’s decision to slash customs duty on some of the medicines and excise duty on all, drug makers will get over a fo...

Small firms often do not have resources to develop their intellectual property. Patents give them something they desperately need: reputati...

For companies big and small CRM has become a necessity - SMEs in particular have realised its vast importance.